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PRAS40 has recently been identified as a protein that
couples insulin/IGF signaling (IIS) to TORC1 activa-
tion in cell culture; however, the physiological func-
tion of PRAS40 is not known. In this study, we inves-
tigate flies lacking PRAS40. Surprisingly, we find
both biochemically and genetically that PRAS40
couples IIS to TORC1 activation in a tissue-specific
manner, regulating TORC1 activity in ovaries but
not in other tissues of the animal. PRAS40 thereby
regulates fertility but not growth of the fly, allowing
distinct physiological functions of TORC1 to be
uncoupled. We also show that the main function of
PRAS40 in vivo is to regulate TORC1 activity, and
not to act as a downstream target and effector of
TORC1. Finally, this work sheds some light on the
question of whether TORC1 activity is coupled to
IIS in vivo.
INTRODUCTION
TOR complex 1 (TORC1) and insulin/IGF signaling (IIS) are two
highly conserved pathways that sense nutrient status in animals
from flies to humans. IIS is responsive to hormonal cues, thereby
integrating information about organismal nutrient status. In
contrast TORC1 signaling, which is conserved in unicellular
organisms, senses primarily cell-autonomous information such
as cellular stress, energy, and nutrients (Avruch et al., 2006;
Kwiatkowski and Manning, 2005; Martin and Hall, 2005; Shaw,
2009). Both IIS and TORC1 integrate this information to regulate
multiple physiological processes including carbohydrate metab-
olism, lipid metabolism, tissue growth, fertility and lifespan in
a manner that is conserved from flies to mammals (Fontana
et al., 2010; Goberdhan and Wilson, 2003; Grewal, 2009; Kozma
and Thomas, 2002; Nakae et al., 2001). Of note, TORC1 is one of
the most powerful anabolic signals in cells, regulating cellular
growth via modulation of protein and lipid biosynthesis, leading
to cellular mass accumulation. As a consequence TORC1 is
hyperactivated in almost all cancers (Bjornsti and Houghton,
2004; Guertin and Sabatini, 2007).
The connection between IIS and TORC1 has been a matter of
debate. In human and Drosophila tissue culture cells, treatment
with insulin leads to rapid TORC1 activation (Cai et al., 2006;172 Developmental Cell 22, 172–182, January 17, 2012 ª2012 ElseviHahn et al., 2010; Inoki et al., 2002; Manning et al., 2002; Potter
et al., 2002), indicating the two pathways are linked. Less clear
is whether this link is functionally relevant for cells in an animal
under physiological conditions. Studies in Drosophila have
suggested this is not the case. One molecular link connecting
IIS to TORC1 is the TSC1/2 complex. In cell culture, phosphory-
lation of Tsc2 by Akt inactivates it, thereby relieving its suppres-
sion of TORC1 (Cai et al., 2006; Inoki et al., 2002; Manning et al.,
2002; Potter et al., 2002). However, inDrosophila in vivo, removal
of the Akt phosphorylation sites on Tsc1 and Tsc2 leads to no
defects in TOR activation and no physiological consequences
(Dong and Pan, 2004; Schleich and Teleman, 2009), suggesting
that although this molecular link exists, it does not play an impor-
tant functional role under physiological conditions. Although one
explanation could be the presence of redundant molecular
mechanisms linking IIS to TORC1, this appears not to be the
case. In Drosophila larvae, reduction of IIS either via removal of
the insulin receptor substrate chico, or via reduction of PI3K
activity (Dp110A), has no effect on activity of S6K and hence
TORC1 (Oldham et al., 2000; Radimerski et al., 2002), raising
the question whether TORC1 activation is at all linked to IIS
in vivo under physiological conditions. Because of the central
role TORC1 plays in regulating cellular growth and metabolism,
a better understanding of the mechanisms regulating its activity
would have implications for both normal and pathophysiological
conditions such as cancer, metabolic disease, or infertility.
Recently the protein PRAS40 has been proposed to link IIS
to TORC1 in cell culture. Two reports showed that PRAS40
binds the TORC1 complex thereby inhibiting its activity, and
that phosphorylation of PRAS40 by Akt relieves this inhibition
(Nascimento et al., 2010; Sancak et al., 2007; Vander Haar
et al., 2007). Three other studies, however, identified PRAS40
as a TORC1 substrate, suggesting that the apparent inhibitory
effects of PRAS40 on the canonical TORC1 substrates 4EBP
and S6K may reflect competition for substrate binding (Fonseca
et al., 2007; Oshiro et al., 2007; Wang et al., 2007). This would
place PRAS40 downstream, rather than upstream of TORC1.
Indeed, as these studies point out, PRAS40 might function
concomitantly as a TORC1 substrate and a TORC1 regulator,
regulating mTORC1 activity via direct inhibition of substrate
binding. These studies have led to several open questions: (1)
does PRAS40 regulate TORC1 activity in vivo, as it does in cell
culture? (2) does PRAS40 link IIS to TOR activation in vivo?
and (3) is the main function of PRAS40 to act as a TOR substrate
or as a TOR regulator? These two options can be distinguished in
an animal context. If the main function of PRAS40 is to regulateer Inc.
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PRAS40 mutant phenotypes should be rescued by reducing
activity of TORC1 or of a TORC1 target other than PRAS40. If,
instead, PRAS40 functions mainly as a TOR substrate down-
stream of TORC1, then loss of PRAS40 cannot be rescued by
manipulating TORC1. To our knowledge, no animal models for
PRAS40 loss of function have yet been reported to address
these questions.
One physiological function of IIS and TORC1 of particular
relevance to this present study is the regulation of fertility. In
Drosophila, insulin-like peptides (DILPs) secreted by neurose-
cretory cells regulate the rate of germline stem cell division in
the ovary (LaFever and Drummond-Barbosa, 2005). This links
metabolic status to fertility, so that rich nutrient conditions
cause high DILP secretion, leading to increased egg production.
If IIS is abrogated in the ovary, as in the case of chico or InR
mutants, egg production is completely blocked and the animals
are sterile (Bo¨hni et al., 1999; Brogiolo et al., 2001; Drummond-
Barbosa and Spradling, 2001). The defect in chico mutant
ovaries is ovary-autonomous because transplantation of chico
mutant ovaries into wild-type hosts, containing normal levels of
DILPS, does not rescue their defects (Richard et al., 2005). At
the cellular level, IIS and TORC1 regulate almost all aspects of
oogenesis including the rate of proliferation of ovarian somatic
and germline cells, germline stem cell maintenance, vitellogen-
esis, and oocyte loss (Drummond-Barbosa and Spradling,
2001; Hsu and Drummond-Barbosa, 2009; Hsu et al., 2008;
LaFever et al., 2010; Sun et al., 2010; Thomson et al., 2010).
Interestingly, the roles of IIS and TORC1 in regulating fertility
are highly conserved throughout evolution, regulating similar
processes in Caenorhabditis elegans (Michaelson et al., 2010)
and in mammals. As in flies, reduction of IIS via knockout of
IGF-1 or IRS-2 causes infertility in mice (Baker et al., 1993; Burks
et al., 2000). As in flies, normal TORC1 in mice prevents oocyte
loss (Thomson et al., 2010) and hyperactivation of IIS or
TORC1 leads to premature activation of all primordial follicles,
resulting in premature follicular depletion (Reddy et al., 2010;
Sun et al., 2010). In sum, IIS and TORC1 play critical roles in
regulating fertility in an evolutionarily conserved manner.
We present here a PRAS40 loss-of-function animal model.
By generating PRAS40 knockout Drosophila, we study the
in vivo function of PRAS40, as well as the connection between
IIS and TORC1. We show that PRAS40 does function to link IIS
to TORC1 in the animal. Unexpectedly, however, we find that it
does so in a tissue-specific manner, influencing TORC1 activity
predominantly in the fly ovary, but not in other tissues of the
animal. As a result, PRAS40 regulates development of the
ovary, but not growth or proliferation of somatic tissues,
thereby influencing animal fertility but not animal growth.
Because PRAS40 is present in all tissues of the fly, this indi-
cates PRAS40 is a link between IIS and TORC1 that can be
switched on and off in a tissue-specific manner. Furthermore,
we find that PRAS40 knockout phenotypes can be rescued
by inhibiting TORC1 or by reducing S6K gene dosage, indi-
cating that PRAS40 functions mainly as a TORC1 inhibitor
in vivo. Finally, this work sheds light on the conundrum whether
the IIS and TORC1 signaling pathways are linked under normal
physiological conditions, showing that they are indeed linked,
but only in particular tissues.DevelopmRESULTS
CG10109 Is Drosophila PRAS40
A BLAST search of the Drosophila proteome using human
PRAS40 protein sequence identifies CG10109 as the top hit
(E = 104). Conversely, BLASTing the human proteome with
CG10109 identifies hPRAS40 as a top hit, establishing an
orthology relationship between hPRAS40 and CG10109, in
agreement with previous reports (Sancak et al., 2007). The
CG10109 coding sequence was previously associated with
a mutant phenotype called Lobe (Chern and Choi, 2002; Wang
and Huang, 2009). Lobe alleles cause preferential loss of the
ventral eye domain due to aberrant Notch and JAK/STAT
signaling (Chern and Choi, 2002). Although the Lobe alleles
were mapped to the 51A2-B1 genomic region, which also
contains CG10109, to our knowledge they were not molecularly
mapped to the CG10109 gene. Although Lobe loss-of-function
alleles such as Lrev6-3 are lethal (Chern and Choi, 2002), we found
they are rescued to viability without any obvious phenotype
when put in trans to a deficiency uncovering the CG10109 locus,
Df(2R)ED2354, suggesting Lobe does not map genetically
to CG10109. Furthermore, we tried to rescue viability of the
Lrev6-3 allele using a UAS-CG10109 transgene but were unable
to do so. Because these results raise the possibility that Lobe
might not correspond to CG10109, we undertook a de novo
analysis of CG10109 function, which we rename here dPRAS40.
We first tested whether dPRAS40 has the biochemical charac-
teristics previously described for human PRAS40—that it binds
Raptor and is phosphorylated on T246 in response to insulin
stimulation. A protein alignment of dPRAS40 and hPRAS40
reveals that both the Akt phosphorylation motif containing
Thr246 and the Raptor binding motif (TOS) are conserved
(RPRLRS and FDLED, respectively). We expressed HA-tagged
dPRAS40, immunoprecipitated (IP) it from Kc cells, and tested
its phosphorylation status using a ‘‘phospho Akt substrate’’ anti-
body recognizing the phosphorylated R-x-R-x-x-p(S/T) motif.
This revealed that insulin stimulation causes a marked induction
in PRAS40 phosphorylation (Figure 1A, lanes 3 and 4). This phos-
phorylation is abrogated if Ser558, the equivalent site to Thr246
in hPRAS40, is mutated to alanine (Figure 1A, lanes 5 and 6), indi-
cating that the phospho-signal is specific for S558. We next
tested whether dPRAS40 can bind dRaptor by co-IP in S2 cells,
and this was indeed the case (Figure 1B).
We next studied the physiological consequences of
dPRAS40 overexpression. Overexpression of PRAS40 specifi-
cally in the posterior half of the fly wing using engrailed-GAL4
caused a marked reduction in size of the posterior compart-
ment (Figure 1C). This reduced tissue size was associated
with reduced cell size (Figure 1D) and no defects in patterning
of the veins or of the wing margin. The reduced size of the
posterior compartment could not be rescued by concomitant
expression of the apoptosis inhibitor p35 (Figure 1E), indicating
it is not due to apoptosis. In sum, the observed phenotypes of
PRAS40 overexpression are consistent with an effect on
TORC1, which regulates tissue size mainly via regulation of
cell size. Consistent with this, overexpression of Rheb, an
upstream activator of TORC1, was able to partially rescue the
undergrowth caused by PRAS40 overexpression (Figure 1F).
These gain-of-function effects were not specific for the wing,ental Cell 22, 172–182, January 17, 2012 ª2012 Elsevier Inc. 173
Figure 1. Overexpression of CG10109, Drosophila PRAS40, Causes Tissue Undergrowth
(A) Drosophila PRAS40 is phosphorylated on Ser558 in response to insulin. Kc cells were stimulated +/ 10 mg/mL insulin for 60 min prior to lysis. Immuno-
precipitated HA-PRAS40 was then probed with phospho-Akt-substrate antibody recognizing the phospho-motif R-x-R-x-x-(S/T)*. Phosphorylation of PRAS40
increased upon insulin stimulation, but not if Ser558 was mutated to alanine.
(B) Drosophila PRAS40 and Raptor interact physically. FLAG-dPRAS40 and HA-dRaptor were expressed in S2 cells and anti-FLAG immunoprecipitates were
probed as indicated. A GFP-expression construct was used to normalize DNA amounts in the transfection.
(C) Overexpression of PRAS40 in the posterior compartment of the wing causes reduced tissue growth. Wings of engrailed-GAL4, UAS-PRAS40 flies show
a marked reduction in size of the posterior compartment, compared to the parental genotypes that do not overexpress PRAS40.
(D) PRAS40 overexpression causes reduced cell size. Cell size of posterior wing cells determined by quantifying hairs per unit area in wings expressing either
GFP or PRAS40 in the posterior compartment with engrailed-GAL4. Relative size of posterior cells versus control anterior cells is indicated (n = 10).
(E) Undergrowth caused by PRAS40 overexpression is not rescued by the apoptosis inhibitor p35. Quantification of posterior versus control anterior area of
wings expressing p35, PRAS40, or both in the posterior compartment with engrailed-GAL4. UAS-GFP was used as a normalization to counteract possible
GAL4 titration effects (n = 12).
(F) Overexpression of PRAS40 and Rheb counteract each other phenotypically. Posterior versus anterior area for wings of indicated genotypes. Overexpression
of Rheb partially rescues the reduced growth caused by PRAS40 overexpression.
In all panels, ***Mann-Whitney U < 0.001, error bars denote SD.
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Drosophila PRAS40as overexpression in the eye caused reduced eye size (see Fig-
ure S1A available online) and ubiquitous overexpression with
actin-GAL4 caused reduced size of the entire animal and pupal
lethality (Figure S1B).
PRAS40– Flies Are Viable and Normally Sized
To study the function of endogenous PRAS40 in Drosophila, we
generated a CG10109 loss-of-function allele by homologous
recombination-mediated gene knockout (PRAS40KO, Figure 2A).
We knocked-out 500 bp of coding sequence from the second
exon, replacing it with the mini white gene, causing the
remainder of the gene to be out of frame, yielding a predicted
null allele. Indeed, PRAS40 animals had no detectable
PRAS40 protein (Figure S2A), and their phenotypes were not
exacerbated by placing the mutation in trans to a deficiency
uncovering the locus (data not shown). We backcrossed female
flies harboring the PRAS40KO mutation to w1118 flies for five
generations, obtaining two stocks with similar genetic back-174 Developmental Cell 22, 172–182, January 17, 2012 ª2012 Elsevigrounds but differing by presence or absence of the PRAS40
knockout. The resulting stocks were used for all experiments
described here, and we refer to them as ‘‘PRAS40mutant’’ flies,
and the w1118 stock as ‘‘controls.’’
Surprisingly, PRAS40 mutant flies are viable to adulthood,
fertile, and have no obvious eye patterning defects (Figure 2B).
This was surprising becausemutations in other known regulators
of TOR such as Tsc1, Tsc2, or Rheb, are all lethal. Also contrary
to our expectation, PRAS40 knockouts are normal in size.
The weight of both male and female flies is indistinguishable to
those of controls (Figure 2C). Quantification of wing and cell
size in PRAS40 mutants also revealed no difference compared
to controls (Figure 2D). This was unexpected from the proposed
role of PRAS40 as a TOR regulator, and given that PRAS40
overexpression has clear effects on tissue size (above). The
pupation rate of PRAS40 flies also did not differ significantly
from that of controls (Figure 2E), indicating that PRAS40mutants
have a normal rate of growth. One possible explanation forer Inc.
Figure 2. PRAS40– Flies Are Viable andHave
Normal Size
(A) Schematic representation of the CG10109/
PRAS40 locus. Knock-out region is indicated.
(B) Images of eyes from w1118 (control) and
PRAS40 flies.
(C) PRAS40 mutants have normal body weight.
Weight per fly for control and PRAS40males and
females (n = 8, done in quadruplicate).
(D) PRAS40 mutants have normal wing size and
cell size. Total wing size of control and PRAS40
females, as well as cell size (quantified via hair
density), are shown (n = 11).
(E) PRAS40 mutants are not significantly delayed
in development. Pupation curves for control and
PRAS40 flies. One hundred animals per vial, 10
vials for each genotype.
(F) Flies simultaneously lacking all Akt phosphor-
ylation sites on Tsc1 and Tsc2, as well as PRAS40,
are normal in size. ‘‘Tsc1(A),Tsc2(4A)’’ indicates
flies are mutant for endogenous Tsc1 and Tsc2
(Tsc129,gig192) and contain constructs constitu-
tively expressing mutant versions of Tsc1 and
Tsc2 in which all Akt phosphorylation sites are
mutated to alanine as previously described
(Schleich and Teleman, 2009). Wing size relative to
control wings is indicated (n = 8–2).
(G) Phosphorylation of S6K is not elevated in
PRAS40 larvae. Total protein extracts from
wandering third instar larvae probed with anti-
phospho-S6K(Thr398), a readout for TORC1
activity.
In all panels, error bars denote SD.
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PRAS40 and the Tsc1/Tsc2 complex form redundant mecha-
nisms connecting IIS to TORC1. To test this, we generated flies
in which both Tsc1 and Tsc2 were replaced with mutant versions
that could not be phosphorylated by Akt (Dong and Pan, 2004;
Schleich and Teleman, 2009), simultaneously harboring the
PRAS40 mutation (‘‘PRAS40, Tsc1(A), Tsc2(4A)’’ flies). These
flies were also viable and normal in size (Figure S2B), and quan-
tification of their wing size revealed no differences compared to
controls (Figure 2F). Because manipulation of TORC1 activity
during Drosophila development causes clear and dramatic
effects on final organismal size, these data suggested that
removal of PRAS40 does not reduce TORC1 activity during
development. To test this, we assayed phosphorylation levels
of S6K on Thr398, an established readout for TORC1 activity,
in third instar larvae by western blot analysis (Figure 2G). Consis-
tent with a lack of size phenotypes in PRAS40 knockouts, we
could detect no reduction in phospho-S6K levels in the mutant
larvae (Figure 2G). In sum, these data suggest PRAS40 does
not regulate TORC1 activity in Drosophila during growth of the
animal.Developmental Cell 22, 172–182PRAS40 Links IIS to TORC1 in
Ovaries but Not Adult Soma
We next tested whether TORC1 activity is
aberrant in PRAS40 adults. Contrary to
the situation in larvae, phosphorylation
of the two canonical TORC1 targets 4E-BP and S6K was mildly elevated in PRAS40 adults compared
to controls (Figure 3A). Interestingly, the increase in TORC1
activity appeared to be of larger magnitude in females compared
to males (Figure 3A, top). One difference between female and
male flies is that a substantial fraction of the female body is
comprised of ovaries. We therefore tested whether TORC1
activity is elevated in the ovaries of PRAS40 knockouts. We
separated ovaries from the rest of the female body and
performed western blot analysis on these two fractions. Surpris-
ingly, phospho-S6K levels were dramatically increased in
ovaries of PRAS40 mutants (Figure 3B, lanes 1 and 2), whereas
there was no detectable difference in phospho-S6K levels in
the remainder of the female body compared to controls (Fig-
ure 3B, lanes 5 and 6). This unexpected result indicates that
the observable difference in TORC1 activity levels in adult
females derives mainly from elevated TORC1 activity in ovaries.
Furthermore, it indicates that endogenous PRAS40 represses
TORC1 in ovaries but not in the rest of the female body.
In cell culture, PRAS40 links IIS activation to TORC1 activation
(Nascimento et al., 2010; Sancak et al., 2007; Vander Haar et al.,
2007). We tested whether this is also the case in vivo in the fly, in, January 17, 2012 ª2012 Elsevier Inc. 175
Figure 3. PRAS40 Links IIS to TORC1 in Ovaries but Not in Rest
of Body
(A) TORC1 activity is mildly elevated in PRAS40 adult flies, with a more
significant effect in females. Total body protein extracts from PRAS40 or
control flies were probed with antibodies detecting phosphorylation of S6K on
Thr398 and 4E-BP on Thr37/Thr46, two readouts for TORC1 activity.
(B) TORC1 activity is elevated specifically in ovaries of PRAS40 females, and
removal of PRAS40 rescues the reduced S6K phosphorylation of chico1
mutant ovaries. Female flies of indicated genotypes were dissected into
‘‘ovaries’’ and ‘‘rest of body’’ and protein extracts were probed with indicated
antibodies.
(C) Increase in TORC1 activity in response to activation of PI3K is blunted in
PRAS40 ovaries but not in the rest of the animal. Female flies carrying
heatshock-GAL4, UAS-Dp110-CAAX were heat-shocked for 30 min at 37C
and allowed to recover for 6 hr. Ovaries were separated from the rest of the
body and protein extracts were probed with indicated antibodies.
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176 Developmental Cell 22, 172–182, January 17, 2012 ª2012 Elsevithe adult ovary where PRAS40 represses TORC1. We first
reduced IIS via removal of the insulin receptor substrate chico
and monitored TORC1 activity via phosphorylation of S6K.
Chico1 homozygous null animals had significantly reduced S6K
phosphorylation in ovaries (Figure 3B, lane 1 versus lane 3) but
not in the rest of the body (Figure 3B, lanes 5–8), the latter being
in agreement with previous reports that loss of chico does not
affect TORC1 activity (Oldham et al., 2000; Radimerski et al.,
2002). This indicates that unlike most tissues of the fly, in the
ovary IIS and TORC1 are linked. In contrast, chico1 null animals
had reduced Akt phosphorylation in both ovaries and the rest of
the body, as observed by others (Werz et al., 2009). We next
asked whether this differential coupling between IIS and
TORC1 is due to PRAS40. Indeed, removal of PRAS40 in the
chico1 mutant rescued pS6K levels back to normal in ovaries
(Figure 3B, lane 1 versus lane 4). In contrast, simultaneous
removal of chico and PRAS40 had no effect in the rest of the
female body (Figure 3B, lane 8) consistent with the phenotype
of the single mutants.
In a set of complementary experiments, we increased IIS by
expressing heat-shock inducible activated PI3K (hsGAL4,
UAS-Dp110-CAAX), and assessed the effect on TORC1 activity
in ovaries versus rest of the body (Figure 3C). In this case,
ectopic activation of IIS caused increased S6K phosphorylation
in the soma of both control and PRAS40- adult females
(Figure 3C, lanes 5–8). This is consistent with many findings
that stimulation of IIS above physiological levels can induce
TORC1 activity, for instance in cell culture or in explants of larval
tissues (data not shown), whereas modulation of IIS within
physiological range does not (Figure 3B). In the same animals,
ectopic activation of IIS also induced S6K phosphorylation in
ovaries of control animals (Figure 3C, lanes 1 and 2) however
the magnitude of induction was strongly blunted in PRAS40
ovaries (Figure 3C, lanes 3 and 4). In sum, both experiments,
either increasing or decreasing IIS, indicate that PRAS40 is
required for IIS to properly activate TORC1 in the ovaries but
not in the rest of the body.
PRAS40 Rescues the Sterility of IIS Loss-of-Function
Conditions and Regulates Fertility
The above-mentioned biochemical analyses suggest that
PRAS40 acts epistatically downstream of IIS to regulate
TORC1 specifically in ovaries but not in the rest of the animal.
If this model is correct, it predicts that PRAS40 mutation should
rescue the physiological defects caused by reduced IIS in
ovaries but not in the rest of the animal.We tested this via genetic
epistasis experiments. As mentioned above, PRAS40 mutant
females are fertile and normally sized compared to controls
(Figure 4A). In contrast, as previously reported (Bo¨hni et al.,
1999), chico1 homozygous females have significantly reduced
body size and are completely sterile (Figure 4A). Consistent
with the model mentioned above, introducing the PRAS40
mutation into the chico1 mutant background does not rescue
the reduced body size of chico mutants (Figure 4A). The wing
size of chico1, PRAS40 females is the same as that of chico1
mutants, and 60% that of control flies (Figure 4B). Likewise,
the reduced wing cell size of chico1 mutants was not rescued
by removal of PRAS40 (Figure 4C). Strikingly, however, removal
of PRAS40 completely rescues the infertility of chico1 females.er Inc.
Figure 4. PRAS40 Mutation Rescues the
Sterility of chico Mutant Flies, But Not Their
Reduced Body Size
(A) Removal of PRAS40 in the chico1 background
rescues the fertility of chico1 flies, but not their
reduced size. Images of female flies of indicated
genotypes, grown under growth-controlled
conditions. The overall body size of chico1,
PRAS40 flies is the same as that of chico1 flies
(e.g., head size or wing size) but the abdomen has
the normal ‘‘inflated’’ appearance of fertile
females.
(B) Removal of PRAS40 does not rescue the
reduced size of chico mutants. Wing size of
females, relative to controls, of indicated geno-
types, grown under growth-controlled conditions.
***t test = 1016. n.s., not significant (t test = 0.27)
(n > 10).
(C) Removal of PRAS40 does not rescue the
reduced cell size of chico mutants. Wing cell size,
relative to controls, quantified by measuring hairs
per unit area, in wings of females of indicated
genotypes, grown under growth-controlled
conditions. ***t test = 105. n.s., not significant
(t test = 0.85) (n > 10).
(D) Removal of PRAS40 rescues the infertility of
chico mutant females. Ovaries from females of
indicted genotypes. Chico1 ovaries halt develop-
ment prior to vitellogenesis, whereas chico1,
PRAS40 ovaries contains fully developed eggs.
(E and F) PRAS40 females lay more eggs per day
than controls, and this phenotype is rescued by
expressing PRAS40 ubiquitously with heatshock-
GAL4 (E) or specifically in the germline with nanos-
GAL4 (F). Eggs laid per fly per day in the presence
of yeast is shown for indicated genotypes. Flies
were aged 11–14 days (E) or 5–6 days (F) post-
eclosion and the experiment done at 29C without
heat shock (E) or 25C (F). **t test < 0.01, ***t test <
0.001 relative to PRAS40 for the respective day
(n > 10 flies, done in quadruplicate).
(G) The increased egg-laying rate of PRAS40
females is rescued by feeding rapamycin. Rapa-
mycin was supplemented in food at 200 mM for
5days in theabsenceof yeast. Twenty-five females
per tube, done in triplicate. *t test = 0.04. n.s.,
not significant (t test = 0.6) (n = 25 flies, done in
triplicate).
(H) The increased egg-laying rate of PRAS40
females is rescued by removing one copy of S6K.
Assay done in presence of yeast. S6K+/ indi-
cates S6K07084/+. **t test = 0.002, n.s., = not
significant (t test = 0.89) (n = 15 flies, done in
triplicate).
In all panels, error bars denote SD.
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controls, due to absence of fully-developed ovaries, whereas
the abdomens of chico1, PRAS40 females have the usual in-
flated appearance (Figure 4A). Dissection of the ovaries from
these animals revealed that chico1 ovaries do not have cysts
reaching the vitellogenic stage, whereas ovaries from chico1,
PRAS40 double mutants contain cysts of all stages including
fully-developed eggs (Figure 4D). The total size of chico1,DevelopmPRAS40 ovaries is reduced compared to those of control
females, fitting with the reduced total body and abdomen size
of these animals (Figures 4A and 4D). chico1, PRAS40 females
nonetheless lay viable eggs, and chico1, PRAS40 animals can
be maintained as a viable homozygous stock (data not shown).
Interestingly, the eggs laid by chico1, PRAS40 mutant females
are small (Figures S3A and S3A0). In sum, PRAS40 acts epistati-
cally downstream of chico specifically in the ovary, rescuing theental Cell 22, 172–182, January 17, 2012 ª2012 Elsevier Inc. 177
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Drosophila PRAS40infertility of chico mutant animals, but not their reduced body
size, in agreement with PRAS40 linking IIS to TORC1 in ovaries
but not in the rest of the body. Intriguingly, mutation of
PRAS40 also rescues the infertility of PDK14/5 females and
males, suggesting that PRAS40 may function also in the male
gonad (data not shown). Indeed, a mild increase in TORC1
activity can also be observed in total extracts from adult males
(Figure 3A).
Ovaries from PRAS40 females appear larger than those of
control females (Figure 4D). This is consistent with PRAS40
ovaries having elevated levels of phospho-S6K in comparison
to controls (Figure 3B). Therefore, we asked whether PRAS40
also regulates fertility in a wild-type background where IIS is
normal. Indeed, PRAS40 females lay significantly more eggs
than controls, reaching up to three times as many eggs per
day as controls, depending on culturing conditions and fly age
(Figure 4E). This phenotype can be rescued by reintroducing
PRAS40 via a UAS construct driven by heat-shock-GAL4
(Figure 4E). TORC1 regulates almost all aspects of oogenesis
including the rate of proliferation of ovarian somatic and germline
cells, germline stem cell maintenance, vitellogenesis, and
oocyte loss (Drummond-Barbosa and Spradling, 2001; Hsu
and Drummond-Barbosa, 2009; Hsu et al., 2008; LaFever
et al., 2010; Sun et al., 2010; Thomson et al., 2010). Consistent
with this, we could detect PRAS40 protein in all cells of the ovary,
including follicle cells, nurse cells, oocytes, and cells of the ger-
marium (Figures S4A and S4B). PRAS40 staining is diffusely
cytoplasmic with intensely-staining cytoplasmic speckles.
PRAS40 levels appear strongest in the germarium and during
early stages of egg development (Figures S4A and S4B). Reintro-
ducing PRAS40 specifically in the germline using nanos-GAL4
rescues the elevated fertility phenotype of PRAS40 mutants
(Figure 4F). Therefore, although PRAS40 may also be acting in
the somatic ovary, germline expression of PRAS40 appears to
be sufficient to rescue the phenotype. Intriguingly, testes from
PRAS40 mutant males are also enlarged compared to controls
(Figure S4C), raising the possibility that PRAS40 also regulates
male fertility.
One open question regarding PRAS40 is whether its main role
is to function as a regulator of TORC1 (perhaps via competition
for TORC1 binding with S6K and 4E-BP) or whether its main
function is to act as a downstream target of TORC1. This can
be tested in vivo. If the phenotypes of PRAS40 flies result
from elevated TORC1 activity, they should be rescued by
reducing activity of TORC1 or a TORC1 effector such as S6K.
If instead PRAS40 acts downstream of TORC1 as a TORC1
effector, then the absence of PRAS40 cannot be rescued by
manipulating activity levels of TORC1 or other TORC1 targets.
To address this, we first asked whether the increased fertility
of PRAS40mutants can be rescued by feeding them rapamycin,
which inhibits TORC1. Indeed, this was the case (Figure 4G).
Most of the effect of TORC1 on fly fertility has been ascribed
to S6K (LaFever et al., 2010; Montagne et al., 1999). Therefore,
as a more stringent test, we asked whether the increased fertility
of PRAS40 mutants can be rescued by reducing S6K gene
dosage. Indeed, removing one copy of S6K brought the egg
laying of PRAS40 mutants back down to control levels
(Figure 4H). This indicates the increased fertility of PRAS40
knockouts is mainly due to elevated S6K activity, suggesting178 Developmental Cell 22, 172–182, January 17, 2012 ª2012 Elsevithat the main physiological function of PRAS40 is to act as
a TORC1 inhibitor.
Tissue-Specific Function of PRAS40
Both the biochemical data and the genetic data presented above
suggest that PRAS40 functions in a tissue-specific manner,
regulating TORC1 activity in ovaries but not in other tissues of
the adult or in larvae. One possible explanation is that PRAS40
is expressed specifically in ovaries. We performed quantitative
RT-PCR to detect PRAS40 expression and found that it is ex-
pressed at all developmental stages of the animal (Figure 5A).
In third instar larvae, PRAS40 is expressed in all tissues that
we assayed, with relative enrichment in the intestine (Figure 5B).
In adults, PRAS40 was expressed in ovaries, in the female gut,
and in the remainder of the female body, as well as in testis,
with relative enrichment in the ovary (Figure 5C). Likewise,
PRAS40 protein could be detected in all assayed tissues and
developmental stages (Figures S5A and S5B). Therefore,
PRAS40 is not expressed only in adult ovaries. PRAS40 is
thought to regulate S6K phosphorylation via competition for
substrate binding to TORC1. Another possible explanation for
why PRAS40 functions in a tissue-specific manner might be
that this competition mechanism functions in ovaries but not in
other tissues of the animal. However, we find no evidence for
substrate competition in the ovary because removal of another
TORC1 target, 4E-BP, does not lead to elevated levels of S6K
phosphorylation on Thr398 (Figure 5D). Having excluded these
two possibilities, one remaining possibility is that the activity of
PRAS40 is regulated in a tissue-specific manner, for instance
by posttranslational modification. If PRAS40 were not functional
in tissues other than the ovary, this would explain why removing
it has no consequences. To test this possibility, we performed
isoelectric focusing (IEF) of proteins from various tissues of the
animal, followed by western blotting to detect endogenous
PRAS40. On an IEF gel, PRAS40 formsmultiple bands of varying
pI (Figure 5E), in agreement with it being phosphorylated on
multiple sites (Nascimento et al., 2010; Wang et al., 2008).
Interestingly, PRAS40 was significantly more shifted toward
isoforms with higher pI in extracts from ovaries compared to
extracts from larvae or adult males (lacking ovaries) (Figure 5E),
indicating that the state of posttranslational modification of
PRAS40 is different in ovaries compared to other tissues. We
favor the possibility that PRAS40 is maintained in an inactive
state in tissues other than ovaries. This would explain why reduc-
tion of IIS via removal of chico causes reduced TORC1 activity in
ovaries but not in other tissues (Figure 3B). Consistent with this,
the isoelectric focusing of PRAS40 in ovaries changed in
response to treatment with wortmannin (Figure S5C) whereas
the isoelectric focusing of PRAS40 in larval tissues was compar-
atively wortmannin unresponsive (Figure S5C). These observa-
tions suggest that tissue-specific factors may be regulating the
ability of PRAS40 to respond to insulin, however further work
will be necessary to decipher these mechanisms.
DISCUSSION
The question whether IIS is coupled to TORC1 in vivo has been
an issue of debate, because activation of TORC1 in response
to IIS can be observed in some systems (Cai et al., 2006;er Inc.
Figure 5. PRAS40 Is Differentially Posttranslationally Modified in Ovaries versus Other Tissues
(A–C) PRAS40 expression is not restricted to ovaries. Expression of PRAS40 determined by quantitative RT-PCR relative to rp49 in various tissues and
developmental stages of the fly, as indicated.
(D) Removal of 4E-BP does not lead to increased phosphorylation of S6K on Thr398 in ovaries. Protein extracts from ovaries of w1118 (w), PRAS40, or Thor2
(4E-BP) mutant flies were probed with indicated antibodies.
(E) PRAS40 is differentially posttranslationally modified in ovaries compared to other tissues. Lysates fromwandering third instar larvae (wandering L3), ovaries or
whole adult males were subjected to isoelectric focusing on a pH4–7 gradient, followed by immunoblotting to detect endogenous PRAS40. PRAS40 in ovaries is
more concentrated in isoforms with higher pI compared to other tissues.
(F) Schematic diagram of TORC1 regulation by PRAS40. In the ovary, PRAS40 inhibits TORC1, and this inhibition is relieved by IIS via Akt. In other tissues,
PRAS40 is present but unable to inhibit TORC1 both under high and low IIS conditions, indicating that PRAS40 is held inactive by an IIS/Akt independent
mechanism. This leads to uncoupling of TORC1 from IIS in the rest of the body. Additionally, other factors may be inhibiting TORC1 in rest of body (‘‘X’’).
In all panels, error bars denote SD.
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in others (Dong and Pan, 2004; Hall et al., 2007; Radimerski et al.,
2002). Quite surprisingly, our work suggests that the answer to
whether IIS activates TORC1 in vivo is neither ‘‘yes’’ nor ‘‘no,’’
but rather that it depends in a tissue-specific manner. Both bio-
chemically and genetically we find that PRAS40 and IIS do not
affect TORC1 activity in most tissues during growth of the fly.
Removal of PRAS40 does not cause elevated TORC1 activity
in larvae (Figure 2G) and, in agreement with previous reports
(Oldham et al., 2000; Radimerski et al., 2002), removal of chico
does not lead to reduced TORC1 activity in the adult body
(Figure 3B) or in larvae (data not shown). Removal of PRAS40
does not cause any size abnormalities in the fly, which is
a very sensitive readout for TORC1 activity during development
(Figures 2C and 2D). We were surprised to find, however, that in
ovaries both IIS and PRAS40 do affect TORC1 activity. TORC1
activity drops in ovaries of chico animals, and increases in
ovaries of PRAS40 animals (Figure 3B). Furthermore, in ovaries,
PRAS40 links IIS to TORC1 in that removal of both chico and
PRAS40 leads to renormalized TORC1 activity. These biochem-
ical data are reflected by genetic epistasis data. Chico mutant
flies are completely infertile, laying no eggs, and this phenotype
is rescued by removal of PRAS40 (Figure 4D). These data indi-Developmcate that under normal physiological conditions, IIS activates
TORC1 in a tissue-specific manner.
Does PRAS40 also link IIS to TORC1 in themale germline? The
fact that mutation of PRAS40 rescues the infertility of PDK14/5
mutant males (data not shown), and that PRAS40mutant testes
are larger than control testes (Figure S4C) suggests that it does.
PRAS40, chico mutant testes also appear mildly increased in
size compared to chico mutant testes (Figure S4C), however,
the result is not as clear cut as with ovaries, because chico
mutant females are completely sterile whereas chico mutant
males have only mildly reduced fertility. Further work will be
required to look at this carefully.
All these data, indicating an ovary-specific link between IIS
and TORC1 result from manipulations within physiological
range. In contrast, overexpression of PRAS40 does cause
reduced tissue growth (Figures 1C and 1D; Figure S1) as well
as reduced TORC1 activity (data not shown), indicating that
PRAS40 can inhibit TORC1 inmost tissueswhen overexpressed.
Furthermore, in contrast to the tissue-specific link between IIS
and TORC1 under normal physiological conditions, we also
observe that hyper-stimulation of IIS above physiological range
does activate TORC1 in most tissues, for instance in tissue
explants treated with insulin (data not shown), or in animalsental Cell 22, 172–182, January 17, 2012 ª2012 Elsevier Inc. 179
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Drosophila PRAS40overexpressing activated PI3K (Dp110-CAAX) (Figure 3C). This
mechanism might be relevant for pathophysiological conditions
with elevated IIS, such as in cancer cells. This may occur via
elevated ATP production in the cell, inhibiting AMPK (Hahn
et al., 2010), because we observe this activation also in tissues
simultaneously lacking PRAS40 and all Akt phosphorylation sites
on Tsc1 and Tsc2 (data not shown).
One open question is whether the main function of PRAS40
is to regulate TORC1 activity or whether it functions mainly as
a downstream target and effector of TORC1. Our data suggest
the former is the case. If PRAS40 had effector functions
downstream of TORC1, these functions would not be rescued
by additional removal of other TORC1 substrates such as S6K.
Instead, we find that the elevated fertility of PRAS40 mutants
is rescued by removal of one copy of S6K (Figure 4H), suggest-
ing that the phenotype we find in PRAS40 mutants is due to
elevated S6K activity.
Why does PRAS40 regulate TORC1 activity in ovaries but not
in other tissues of the animal? PRAS40 is expressed in all tissues
that we tested (Figures 5A–5C; Figure S4B). Therefore, the fact
that removal of PRAS40 from larval tissues, for instance, has
no effect on TORC1 activity must mean that larval PRAS40
protein is inactive (Figure 5F). We present data suggesting that
the state of phosphorylation of PRAS40 may be different in
larval tissues compared to ovaries (Figure 5E), providing a
possible explanation for this inactivation. To date, a number of
phosphorylations on PRAS40 have been reported, all of which
are inhibitory in terms of TORC1 binding. These include phos-
phorylations by Akt (Sancak et al., 2007), TORC1 itself (Fonseca
et al., 2007; Oshiro et al., 2007; Wang et al., 2007, 2008), PIM1
(Zhang et al., 2009), and PKA (Blancquaert et al., 2010). Intrigu-
ingly, this correlates with the observation that PRAS40 is highly
phosphorylated in many cancers and that PRAS40 phosphoryla-
tion correlates with bad prognosis (Huang and Porter, 2005;
Johnson et al., 2009; Madhunapantula et al., 2007; McBride
et al., 2010). We favor the possibility that PRAS40 phosphoryla-
tion on an inhibitory site could be regulated by a kinase that is
absent in ovaries, or a phosphatase that is enriched in ovaries
compared to other tissues. Future studies will shed light on
this issue.
TORC1 has multiple physiological roles in various tissues. In
Drosophila, TORC1 in the growing larva regulates both growth
andmetabolism of the animal whereas in the adult fly, it regulates
mainly metabolic parameters. TORC1 in ovaries regulates
fertility of the animal (LaFever et al., 2010; Sun et al., 2010; Zhang
et al., 2006), whereas in the nervous system it regulates dendritic
tiling (Hong and Luo, 2009). Therefore, unless TORC1 activity
can be differentially regulated in various tissues, all these phys-
iological functions would have to be controlled in a correlated
fashion. Tissue-specific differential regulation of PRAS40 pres-
ents a mechanism that allows TORC1 activity to be uncoupled
in a tissue-specific manner.EXPERIMENTAL PROCEDURES
Constructs and Fly Strains
PRAS40 flies were generated by cloning 4 kb of upstream and downstream
genomic flanking sequences into the NotI and XhoI sites of pRK1 (Huang
et al., 2008), respectively. Knockout flies were generated as described in180 Developmental Cell 22, 172–182, January 17, 2012 ª2012 ElseviHuang et al. (2008). Epitope-tagged PRAS40 and raptor were generated by
introducing N-terminal HA or FLAG tags via PCR, and were then cloned into
pMT containing a copper-inducible metallothionein promoter. Sequences of
all oligos used for cloning are provided in the Supplemental Experimental
Procedures.
Antibodies
Anti-4EBP was described (Teleman et al., 2005); anti-CG10109 was a kind gift
from Kwang-Wook Choi (Chern and Choi, 2002). All other antibodies are
described in the Supplemental Experimental Procedures.
Quantitative RT-PCR
RNA was extracted using Trizol (Invitrogen), and reverse-transcribed with
SuperScript III (Invitrogen). Q-PCR was performed using Maxima SYBR
Green/ROX (Fermentas), normalized to rp49. Oligos provided in the Supple-
mental Experimental Procedures .
Isoelectric Focusing
Isoelectric focusing was performed using Servalyte ampholytes (Serva Elec-
trophoresis) in 1-D slab format as described in Unit 10.2 of Current Protocols
in Protein Science (Ploegh, 1995). Culturing of explants is described in the
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
devcel.2011.10.029.
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